The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cross-modality AI modeling of histopathology images to stratify outcomes among patients treated with hormonal or chemo-hormonal therapy in ER+/HER2- breast cancer.
 
Hassan Muhammad
Employment - Pathomiq
Stock and Other Ownership Interests - PathomIQ
 
Shweta Chavan
Employment - PathomIQ
Stock and Other Ownership Interests - PATHMOIQ
Research Funding - PathomIQ
Patents, Royalties, Other Intellectual Property - PathomIQ
 
Chao Feng
Employment - PathomIQ
Stock and Other Ownership Interests - PathomIQ
Research Funding - PathomIQ
Patents, Royalties, Other Intellectual Property - PathomIQ
 
Dianna Almaraz
No Relationships to Disclose
 
Hirak Basu
Stock and Other Ownership Interests - Colby Pharmaceutical Company; PathomIQ
Patents, Royalties, Other Intellectual Property - Colby Pharmaceutical Company; PathomIQ
 
Wei Huang
Employment - Abbott Laboratories (I)
Stock and Other Ownership Interests - PathomIQ
 
Rajat Roy
Employment - PathomIQ
Leadership - PathomIQ
Stock and Other Ownership Interests - PathomIQ
Research Funding - PathomIQ (Inst)
Patents, Royalties, Other Intellectual Property - PATHOMIQ has 3 US patents issued (Inst)
Travel, Accommodations, Expenses - PathomIQ
 
George Wilding
Employment - PathomiQ; Senex Biotechnology
Leadership - AIQ Solutions; PathomIQ; Senex Biotechnology
Stock and Other Ownership Interests - AIQ Solutions; PathomIQ; Senex Biotechnology
 
Gordon Mills
Stock and Other Ownership Interests - BlueDot; Catena; ImmunoMET; Nuvectis Pharma; Robodyne; SignalChem; Tarveda Therapeutics; Turbine
Honoraria - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis Biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Consulting or Advisory Role - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDox; Chrysalis Biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; NeoPhore; Nerviano Medical Sciences; Nuvectis Pharma; Pangea; PDX Pharmacy; Qureator; Roche; Rybodyn; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation of Alabama; Genentech; GlaxoSmithKline; GlaxoSmithKline; Immuno ET; Ionis Pharmaceuticals; Komipharm; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundation; Prospect Creek Foundation; Zentalis
Patents, Royalties, Other Intellectual Property - DSP technology patent with Nanostring; HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); Fortress Biotech; PathomIQ; Sift Biosciences
Consulting or Advisory Role - AADi; Bayer; Boehringer Pharma GmbH; BPGBio; Cadila Pharmaceuticals (I); Daiichi Sankyo; Genome Insight; GI Innovations Inc.; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; MOMA Therapeutics; Mundipharma; Oxford BioTherapeutics; Parabilis; Seagan; SpringWorks Therapeutics; XY One Therapeutics
Research Funding - Adanate Inc. (Inst); ADC Therapeutics (Inst); Alyssum Therapeutics Inc (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Day One Therapeutics (Inst); Deciphera (Inst); Elevation Oncology (Inst); ERASCA, Inc. (Inst); Fog Pharmaceuticals (Inst); Genome & Company (Inst); Gilead Sciences (Inst); GV20 Therapeutics (Inst); Immunitas (Inst); Incyte (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics; Nuvectis Pharma Inc. (Inst); ORIC Pharmaceuticals (Inst); Parabilis (Inst); Pfizer (Inst); PMV Pharma (Inst); Seagen (Inst); Sillajen (Inst); Taiho Pharmaceutical (Inst); Transcenta (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Savitri Krishnamurthy
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Research Funding - Caliber ID; IBEX Medical Analytics; PathomIQ
Patents, Royalties, Other Intellectual Property - Publication of text book from Elsevier